{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:44:16Z","timestamp":1785858256599,"version":"3.56.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    Classic Hodgkin Lymphoma (CHL) remains difficult to treat in patients with relapsed and refractory disease. The utility of immunotherapies, many of which target B-cell markers, is still under investigation. Although the neoplastic Hodgkin and Reed-Sternberg (HRS) cells are thought to lose most B-cell markers, studies have shown retention of these markers, mainly CD20, in some cases. However, the CD19 staining profile of HRS cells has not been thoroughly assessed and warrants exploration in the era of CD19-directed immunotherapies. We assessed CD19 immunohistochemical staining in 41 cases of CHL and correlated with histologic subtype, other markers, and clinical parameters. 13\/41 cases (31.7%) demonstrated CD19 staining in HRS cells, with variation in staining pattern and intensity. When compared with CD19-negative cases, CD19 positivity correlated significantly with mixed-cellularity subtype (53.8% vs. 7.1%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.002), CD20 (46.2% vs. 14.3%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0485), CD79a (53.8% vs. 9.1%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.006), Epstein-Barr Virus (EBV) positivity (53.8% vs. 7.1%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.002), and older age (median age 52 vs. 28.5\u00a0y,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.0006). 7\/9 (77.8%) EBV+ cases demonstrated CD19 expression on HRS cells. By Kaplan-Meier analysis, CD19+ cases demonstrated worse overall survival compared with CD19- cases (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.011), with EBV-, CD19- cases demonstrating the best overall survival. On the basis of these findings, CD19 expression on HRS cells should not preclude the pathologic diagnosis of CHL, particularly in the context of mixed-cellularity or EBV+ disease. In addition, older patients with mixed-cellularity and\/or EBV+ disease may represent a subgroup of patients with CHL who could benefit from CD19-directed therapies.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002519","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:00:08Z","timestamp":1773122408000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-4481","authenticated-orcid":false,"given":"Sarah R.","family":"Helman","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikru","family":"Merechi","sequence":"additional","affiliation":[{"name":"Tower Health, Reading, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alharthy","sequence":"additional","affiliation":[{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Koka","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie Y.","family":"Law","sequence":"additional","affiliation":[{"name":"University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Kallen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Maryland School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"R1-20260731","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20260731","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5644\/ama2006-124.329","article-title":"Classic Hodgkin lymphoma - old disease, new directions: an update on pathology, molecular features and biological prognostic markers","volume":"50","author":"Perry","year":"2021","journal-title":"Acta Med Acad"},{"key":"R3-20260731","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2003.1.225","article-title":"Hodgkin\u2019s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease","volume":"003","author":"Diehl","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R4-20260731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl. 4","key":"R5-20260731","doi-asserted-by":"crossref","first-page":"s5","DOI":"10.1093\/annonc\/7.suppl_4.S5","article-title":"Epidemiology of EBV and Hodgkin\u2019s lymphoma","volume":"7","author":"Jarrett","year":"1996","journal-title":"Ann Oncol"},{"key":"R6-20260731","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"R7-20260731","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/01.MP.0000093627.51090.3F","article-title":"Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases","volume":"16","author":"Tzankov","year":"2003","journal-title":"Mod Pathol"},{"key":"R8-20260731","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"R9-20260731","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2141.2004.04964.x","article-title":"Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin\u2019s disease","volume":"125","author":"Portlock","year":"2004","journal-title":"Br J Haematol"},{"key":"R10-20260731","first-page":"1381","article-title":"Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases","volume":"9","author":"Tzankov","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R11-20260731","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/pin.12175","article-title":"Prognostic significance of CD20 expression and Epstein-Barr virus (EBV) association in classical Hodgkin lymphoma in Japan: a clinicopathologic study","volume":"64","author":"Elsayed","year":"2014","journal-title":"Pathol Int"},{"key":"R12-20260731","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.7150\/jca.13107","article-title":"CD20 over-expression in Hodgkin-Reed-Sternberg cells of classical Hodgkin lymphoma: the neglected quest","volume":"6","author":"Benharroch","year":"2015","journal-title":"J Cancer"},{"key":"R13-20260731","first-page":"1278","article-title":"CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin\u2019s disease: associations with presenting features and clinical outcome","volume":"20","author":"Rassidakis","year":"2002","journal-title":"J Clin Oncol"},{"key":"R14-20260731","doi-asserted-by":"crossref","first-page":"993768","DOI":"10.3389\/fonc.2022.993768","article-title":"CD20 expression is closely associated with Epstein-Barr virus infection and an inferior survival in nodular sclerosis classical Hodgkin lymphoma","volume":"12:","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"R15-20260731","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1080\/10428190802239170","article-title":"CD20 expression by Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall survival in young adult patients","volume":"49","author":"Aldred","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R16-20260731","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2012-06-439455","article-title":"Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival","volume":"121","author":"Venkataraman","year":"2013","journal-title":"Blood"},{"issue":"5-6","key":"R17-20260731","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"R18-20260731","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"R19-20260731","first-page":"474","article-title":"Hodgkin\u2019s disease, mixed cellularity type, with a B-cell immunophenotype. Report of a case and literature review","volume":"119","author":"Siebert","year":"1995","journal-title":"Arch Pathol Lab Med"},{"key":"R20-20260731","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2559.2000.00830.x","article-title":"Varied B-cell immunophenotypes of Hodgkin\/Reed-Sternberg cells in classic Hodgkin\u2019s disease","volume":"36","author":"Watanabe","year":"2000","journal-title":"Histopathology"},{"key":"R21-20260731","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20260731","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R23-20260731","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R24-20260731","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"R25-20260731","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood"},{"key":"R26-20260731","doi-asserted-by":"crossref","first-page":"607362","DOI":"10.3389\/fonc.2020.607362","article-title":"CD19 and CD30 CAR T-cell immunotherapy for high-risk classical Hodgkin\u2019s lymphoma","volume":"10","author":"Xue","year":"2021","journal-title":"Front Oncol"},{"key":"R27-20260731","first-page":"2662","article-title":"The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP","volume":"12","author":"Kozmik","year":"1992","journal-title":"Mol Cell Biol"},{"key":"R28-20260731","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41590-022-01314-y","article-title":"NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia","volume":"23","author":"Witkowski","year":"2022","journal-title":"Nat Immunol"},{"key":"R29-20260731","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"R30-20260731","doi-asserted-by":"crossref","first-page":"153605","DOI":"10.1016\/j.prp.2021.153605","article-title":"PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy","volume":"226","author":"Paolino","year":"2021","journal-title":"Pathol Res Pract"},{"key":"R31-20260731","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"R32-20260731","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2008-06-164806","article-title":"Age-related Epstein-Barr virus (EBV)\u2013associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients","volume":"113","author":"Asano","year":"2009","journal-title":"Blood"},{"key":"R33-20260731","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"R35-20260731","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"R36-20260731","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/modpathol.2009.54","article-title":"Lymphocyte-rich classical Hodgkin\u2019s lymphoma: distinctive tumor and microenvironment markers","volume":"22","author":"Nam-Cha","year":"2009","journal-title":"Mod Pathol"},{"key":"R37-20260731","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/01.MP.0000071843.09960.BF","article-title":"Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin\u2019s lymphoma: a single-institution study","volume":"16","author":"Krugmann","year":"2003","journal-title":"Mod Pathol"},{"key":"R38-20260731","first-page":"2429","article-title":"Adverse clinical outcome in Hodgkin\u2019s disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression","volume":"90","author":"Morente","year":"1997","journal-title":"Blood"},{"key":"R39-20260731","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2008.20.5138","article-title":"Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin\u2019s lymphoma predicts adverse outcome in older adult patients","volume":"27","author":"Diepstra","year":"2009","journal-title":"J Clin Oncol"},{"key":"R40-20260731","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.3390\/v13122523","article-title":"Prognostic role of the expression of latent-membrane protein 1 of Epstein\u2013Barr virus in classical Hodgkin lymphoma","volume":"13","author":"Santisteban-Espejo","year":"2021","journal-title":"Viruses"},{"key":"R41-20260731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"R42-20260731","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.167.1.163","article-title":"The role of the CD19\/CD21 complex in B cell processing and presentation of complement-tagged antigens","volume":"167","author":"Cherukuri","year":"2001","journal-title":"J Immunol"},{"key":"R43-20260731","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1084\/jem.186.5.731","article-title":"Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-\u03baB induction","volume":"186","author":"Sugano","year":"1997","journal-title":"J Exp Med"},{"key":"R44-20260731","doi-asserted-by":"crossref","first-page":"4098235","DOI":"10.1155\/2020\/4098235","article-title":"Effects of Epstein-Barr Virus infection on CD19+ B lymphocytes in patients with immunorelated pancytopenia","volume":"2020","author":"Zhao","year":"2020","journal-title":"J Immunol Res"},{"key":"R45-20260731","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2184.2005.00328.x","article-title":"CD19 signalling improves the Epstein\u2013Barr virus-induced immortalization of human B cell","volume":"38","author":"Hur","year":"2005","journal-title":"Cell Prolif"},{"key":"R46-20260731","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Blood"},{"key":"R47-20260731","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2022","journal-title":"Blood Adv"},{"key":"R48-20260731","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti\u2013PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2023","journal-title":"Blood Adv"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:48:46Z","timestamp":1785854926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002519","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"2025-06-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}